Skip to content

Study · Randomized controlled trial · n = 148 · 2005

6 results

GnRH agonist versus GnRH antagonist in oocyte donation cycles: a prospective randomized study.

Prapas N, Prapas Y, Panagiotidis Y, Prapa S, Vanderzwalmen P, Schoysman R, Makedos G

Human reproduction (Oxford, England)28 Apr 2005Cited by 45 (Europe PMC)

PMID15860501 (opens in a new tab)DOI10.1093/humrep/deh832 (opens in a new tab)PepBankPUB-15860501
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In oocyte donation cycles, clinical pregnancy rates were similar with triptorelin and ganirelix.

    In plain wordsIn oocyte donation cycles, triptorelin and ganirelix produced similar clinical pregnancy rates.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeClinical pregnancy per transfer
    Study

    n = 148

    Comparator
    Ganirelix
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Clinical pregnancy
    41.33%
    triptorelin
    Clinical pregnancy
    39.72%
    ganirelix

    Source sentences

    Summary
    The clinical pregnancy rate per transfer (39.72%, 29/73 versus 41.33%, 31/75) based on transvaginal scan findings at 7 weeks of gestation
    3 context sentences
    Summary · context
    were similar in the two groups.
    Summary · context
    This study was performed to evaluate whether the replacement of GnRH agonist (triptorelin) by a GnRH antagonist (ganirelix; NV Organon) in oocyte donation cycles has any impact on pregnancy and implantation rates.
    Summary · context
    A total of 148 donor IVF cycles was randomly assigned to use either a GnRH antagonist daily administered from the 8th day of stimulation (group I) or a GnRH agonist long protocol (group II) for the ovarian stimulation of their donors.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In oocyte donation cycles, implantation rates were similar with triptorelin and ganirelix.

    In plain wordsIn oocyte donation cycles, triptorelin and ganirelix produced similar implantation rates.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeImplantation rate
    Study

    n = 148

    Comparator
    Ganirelix
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Implantation
    25.4%
    triptorelin
    Implantation
    23.9%
    ganirelix

    Source sentences

    Summary
    the implantation rate (23.9 versus 25.4%) and the first trimester abortion rate (10.34 versus 12.90%) were similar in the two groups.
    2 context sentences
    Summary · context
    This study was performed to evaluate whether the replacement of GnRH agonist (triptorelin) by a GnRH antagonist (ganirelix; NV Organon) in oocyte donation cycles has any impact on pregnancy and implantation rates.
    Summary · context
    A total of 148 donor IVF cycles was randomly assigned to use either a GnRH antagonist daily administered from the 8th day of stimulation (group I) or a GnRH agonist long protocol (group II) for the ovarian stimulation of their donors.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In donor IVF cycles, clinical pregnancy rates at 7 weeks were similar with ganirelix and triptorelin: 39.72% versus 41.33%.

    In plain wordsIn donor IVF cycles, pregnancy rates at 7 weeks were similar with ganirelix and triptorelin.

    Peptide
    Ganirelix
    Outcome
    DecreaseClinical pregnancy per transfer
    Study

    n = 148

    Comparator
    Triptorelin long protocol
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Clinical pregnancy rate
    39.72%
    ganirelix, 29/73
    Clinical pregnancy rate
    41.33%
    triptorelin, 31/75

    Source sentences

    Summary
    The clinical pregnancy rate per transfer (39.72%, 29/73 versus 41.33%, 31/75) based on transvaginal scan findings at 7 weeks of gestation, the implantation rate (23.9 versus 25.4%) and the first trimester abortion rate (10.34 versus 12.90%) were similar in the two groups.
    3 context sentences
    Summary · context
    The primary endpoints were the pregnancy and the implantation rates.
    Summary · context
    This study was performed to evaluate whether the replacement of GnRH agonist (triptorelin) by a GnRH antagonist (ganirelix; NV Organon) in oocyte donation cycles has any impact on pregnancy and implantation rates.
    Summary · context
    A total of 148 donor IVF cycles was randomly assigned to use either a GnRH antagonist daily administered from the 8th day of stimulation (group I) or a GnRH agonist long protocol (group II) for the ovarian stimulation of their donors.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In donor IVF cycles, implantation rates were similar with ganirelix and triptorelin: 23.9% versus 25.4%.

    In plain wordsIn donor IVF cycles, implantation rates were similar with ganirelix and triptorelin.

    Peptide
    Ganirelix
    Outcome
    DecreaseImplantation rate
    Study

    n = 148

    Comparator
    Triptorelin long protocol
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Implantation rate
    23.9%
    ganirelix
    Implantation rate
    25.4%
    triptorelin

    Source sentences

    Summary
    The clinical pregnancy rate per transfer (39.72%, 29/73 versus 41.33%, 31/75) based on transvaginal scan findings at 7 weeks of gestation, the implantation rate (23.9 versus 25.4%) and the first trimester abortion rate (10.34 versus 12.90%) were similar in the two groups.
    3 context sentences
    Summary · context
    The primary endpoints were the pregnancy and the implantation rates.
    Summary · context
    This study was performed to evaluate whether the replacement of GnRH agonist (triptorelin) by a GnRH antagonist (ganirelix; NV Organon) in oocyte donation cycles has any impact on pregnancy and implantation rates.
    Summary · context
    A total of 148 donor IVF cycles was randomly assigned to use either a GnRH antagonist daily administered from the 8th day of stimulation (group I) or a GnRH agonist long protocol (group II) for the ovarian stimulation of their donors.
  5. 05HumanRandomized controlled trialSafety outcome

    In oocyte donation cycles, first trimester abortion rates were similar with triptorelin and ganirelix.

    In plain wordsIn oocyte donation cycles, triptorelin and ganirelix had similar first trimester abortion rates.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeFirst trimester abortion rate
    Study

    n: not reported in source

    Comparator
    Ganirelix
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    First trimester abortion
    12.9%
    triptorelin
    First trimester abortion
    10.34%
    ganirelix

    Source sentences

    Summary
    the first trimester abortion rate (10.34 versus 12.90%) were similar in the two groups.
    2 context sentences
    Summary · context
    This study was performed to evaluate whether the replacement of GnRH agonist (triptorelin) by a GnRH antagonist (ganirelix; NV Organon) in oocyte donation cycles has any impact on pregnancy and implantation rates.
    Summary · context
    A total of 148 donor IVF cycles was randomly assigned to use either a GnRH antagonist daily administered from the 8th day of stimulation (group I) or a GnRH agonist long protocol (group II) for the ovarian stimulation of their donors.
  6. 06HumanRandomized controlled trialSafety outcome

    In donor IVF cycles, first trimester abortion rates were similar with ganirelix and triptorelin: 10.34% versus 12.90%.

    In plain wordsIn donor IVF cycles, first trimester pregnancy loss rates were similar with ganirelix and triptorelin.

    Peptide
    Ganirelix
    Outcome
    DecreaseFirst trimester abortion rate
    Study

    n: not reported in source

    Comparator
    Triptorelin long protocol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    First trimester abortion rate
    10.34%
    ganirelix
    First trimester abortion rate
    12.9%
    triptorelin

    Source sentences

    Summary
    The clinical pregnancy rate per transfer (39.72%, 29/73 versus 41.33%, 31/75) based on transvaginal scan findings at 7 weeks of gestation, the implantation rate (23.9 versus 25.4%) and the first trimester abortion rate (10.34 versus 12.90%) were similar in the two groups.
    2 context sentences
    Summary · context
    This study was performed to evaluate whether the replacement of GnRH agonist (triptorelin) by a GnRH antagonist (ganirelix; NV Organon) in oocyte donation cycles has any impact on pregnancy and implantation rates.
    Summary · context
    A total of 148 donor IVF cycles was randomly assigned to use either a GnRH antagonist daily administered from the 8th day of stimulation (group I) or a GnRH agonist long protocol (group II) for the ovarian stimulation of their donors.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:35 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    22 Oct 2026, 02:26 UTC

    Study results updated

  3. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.